ID   PUR6_HUMAN              Reviewed;         425 AA.
AC   P22234; E9PDH9; Q68CQ5;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 184.
DE   RecName: Full=Multifunctional protein ADE2;
DE   Includes:
DE     RecName: Full=Phosphoribosylaminoimidazole-succinocarboxamide synthase;
DE              EC=6.3.2.6;
DE     AltName: Full=SAICAR synthetase;
DE   Includes:
DE     RecName: Full=Phosphoribosylaminoimidazole carboxylase;
DE              EC=4.1.1.21;
DE     AltName: Full=AIR carboxylase;
DE              Short=AIRC;
GN   Name=PAICS; Synonyms=ADE2, AIRC, PAIS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2253271; DOI=10.1007/BF00318209;
RA   Minet M., Lacroute F.;
RT   "Cloning and sequencing of a human cDNA coding for a multifunctional
RT   polypeptide of the purine pathway by complementation of the ade2-101
RT   mutant in Saccharomyces cerevisiae.";
RL   Curr. Genet. 18:287-291(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-11, ACETYLATION AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V., Potts A., Brablan J., Quadroni M.;
RL   Submitted (JUL-2004) to UniProtKB.
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27 AND THR-238, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27 AND SER-107, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-247, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-107; THR-238 AND
RP   SER-274, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-274, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS), SUBUNIT, ACTIVE SITE, AND
RP   MUTAGENESIS OF HIS-303; SER-332 AND GLY-334.
RX   PubMed=17224163; DOI=10.1016/j.jmb.2006.12.027;
RA   Li S.-X., Tong Y.-P., Xie X.-C., Wang Q.-H., Zhou H.-N., Han Y.,
RA   Zhang Z.-Y., Gao W., Li S.-G., Zhang X.C., Bi R.-C.;
RT   "Octameric structure of the human bifunctional enzyme PAICS in purine
RT   biosynthesis.";
RL   J. Mol. Biol. 366:1603-1614(2007).
CC   -!- CATALYTIC ACTIVITY: ATP + 5-amino-1-(5-phospho-D-
CC       ribosyl)imidazole-4-carboxylate + L-aspartate = ADP + phosphate +
CC       (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-
CC       carboxamido)succinate.
CC   -!- CATALYTIC ACTIVITY: 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-
CC       carboxylate = 5-amino-1-(5-phospho-D-ribosyl)imidazole + CO(2).
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway;
CC       5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide from 5-
CC       amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate: step 1/2.
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway;
CC       5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate from 5-
CC       amino-1-(5-phospho-D-ribosyl)imidazole (carboxylase route): step
CC       1/1.
CC   -!- SUBUNIT: Homooctamer. {ECO:0000269|PubMed:17224163}.
CC   -!- INTERACTION:
CC       Self; NbExp=6; IntAct=EBI-712261, EBI-712261;
CC       P51116:FXR2; NbExp=3; IntAct=EBI-712261, EBI-740459;
CC       Q969R5:L3MBTL2; NbExp=3; IntAct=EBI-712261, EBI-739909;
CC       Q8TBB1:LNX1; NbExp=3; IntAct=EBI-712261, EBI-739832;
CC       Q6ZVK8:NUDT18; NbExp=3; IntAct=EBI-712261, EBI-740486;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P22234-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P22234-2; Sequence=VSP_041265;
CC   -!- SIMILARITY: In the N-terminal section; belongs to the SAICAR
CC       synthetase family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the AIR
CC       carboxylase family. Class II subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X53793; CAA37801.1; -; mRNA.
DR   EMBL; BT006988; AAP35634.1; -; mRNA.
DR   EMBL; CR749824; CAH18683.1; -; mRNA.
DR   EMBL; AC068620; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC114766; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010273; AAH10273.1; -; mRNA.
DR   EMBL; BC019255; AAH19255.1; -; mRNA.
DR   CCDS; CCDS47060.1; -. [P22234-2]
DR   CCDS; CCDS47061.1; -. [P22234-1]
DR   PIR; S14147; S14147.
DR   RefSeq; NP_001072992.1; NM_001079524.1. [P22234-1]
DR   RefSeq; NP_001072993.1; NM_001079525.1. [P22234-2]
DR   RefSeq; NP_006443.1; NM_006452.3. [P22234-1]
DR   UniGene; Hs.518774; -.
DR   UniGene; Hs.709570; -.
DR   PDB; 2H31; X-ray; 2.80 A; A=1-425.
DR   PDBsum; 2H31; -.
DR   ProteinModelPortal; P22234; -.
DR   SMR; P22234; -.
DR   BioGrid; 115852; 83.
DR   IntAct; P22234; 30.
DR   MINT; MINT-5006326; -.
DR   STRING; 9606.ENSP00000382595; -.
DR   ChEMBL; CHEMBL5922; -.
DR   DrugBank; DB00128; L-Aspartic Acid.
DR   iPTMnet; P22234; -.
DR   PhosphoSitePlus; P22234; -.
DR   SwissPalm; P22234; -.
DR   BioMuta; PAICS; -.
DR   DMDM; 131628; -.
DR   EPD; P22234; -.
DR   MaxQB; P22234; -.
DR   PaxDb; P22234; -.
DR   PeptideAtlas; P22234; -.
DR   PRIDE; P22234; -.
DR   DNASU; 10606; -.
DR   Ensembl; ENST00000264221; ENSP00000264221; ENSG00000128050. [P22234-1]
DR   Ensembl; ENST00000399688; ENSP00000382595; ENSG00000128050. [P22234-2]
DR   Ensembl; ENST00000512576; ENSP00000421096; ENSG00000128050. [P22234-1]
DR   GeneID; 10606; -.
DR   KEGG; hsa:10606; -.
DR   UCSC; uc003hbs.1; human. [P22234-1]
DR   CTD; 10606; -.
DR   DisGeNET; 10606; -.
DR   GeneCards; PAICS; -.
DR   HGNC; HGNC:8587; PAICS.
DR   HPA; HPA035895; -.
DR   HPA; HPA041538; -.
DR   MIM; 172439; gene.
DR   neXtProt; NX_P22234; -.
DR   OpenTargets; ENSG00000128050; -.
DR   PharmGKB; PA32914; -.
DR   eggNOG; KOG2835; Eukaryota.
DR   eggNOG; COG0041; LUCA.
DR   eggNOG; COG0152; LUCA.
DR   GeneTree; ENSGT00390000010172; -.
DR   HOGENOM; HOG000082628; -.
DR   HOVERGEN; HBG008335; -.
DR   InParanoid; P22234; -.
DR   KO; K01587; -.
DR   OMA; WQTKNCA; -.
DR   OrthoDB; EOG091G08DN; -.
DR   PhylomeDB; P22234; -.
DR   TreeFam; TF106384; -.
DR   BioCyc; MetaCyc:HS05155-MONOMER; -.
DR   Reactome; R-HSA-73817; Purine ribonucleoside monophosphate biosynthesis.
DR   UniPathway; UPA00074; UER00130.
DR   UniPathway; UPA00074; UER00131.
DR   ChiTaRS; PAICS; human.
DR   EvolutionaryTrace; P22234; -.
DR   GenomeRNAi; 10606; -.
DR   PRO; PR:P22234; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000128050; -.
DR   CleanEx; HS_PAICS; -.
DR   ExpressionAtlas; P22234; baseline and differential.
DR   Genevisible; P22234; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004638; F:phosphoribosylaminoimidazole carboxylase activity; TAS:Reactome.
DR   GO; GO:0004639; F:phosphoribosylaminoimidazolesuccinocarboxamide synthase activity; TAS:Reactome.
DR   GO; GO:0006189; P:'de novo' IMP biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0009113; P:purine nucleobase biosynthetic process; TAS:ProtInc.
DR   GO; GO:0009168; P:purine ribonucleoside monophosphate biosynthetic process; TAS:Reactome.
DR   Gene3D; 3.40.50.7700; -; 1.
DR   HAMAP; MF_02045; PurE_classII; 1.
DR   HAMAP; MF_00137; SAICAR_synth; 1.
DR   InterPro; IPR033626; PurE_classII.
DR   InterPro; IPR000031; PurE_dom.
DR   InterPro; IPR028923; SAICAR_synt/ADE2_N.
DR   InterPro; IPR018236; SAICAR_synthetase_CS.
DR   Pfam; PF00731; AIRC; 1.
DR   Pfam; PF01259; SAICAR_synt; 1.
DR   SMART; SM01001; AIRC; 1.
DR   SUPFAM; SSF52255; SSF52255; 1.
DR   TIGRFAMs; TIGR01162; purE; 1.
DR   PROSITE; PS01057; SAICAR_SYNTHETASE_1; 1.
DR   PROSITE; PS01058; SAICAR_SYNTHETASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Decarboxylase; Direct protein sequencing; Ligase;
KW   Lyase; Multifunctional enzyme; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Purine biosynthesis; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|Ref.6}.
FT   CHAIN         2    425       Multifunctional protein ADE2.
FT                                /FTId=PRO_0000075030.
FT   REGION        2    260       SAICAR synthetase.
FT   REGION      261    266       Linker.
FT   REGION      267    425       AIR carboxylase.
FT   ACT_SITE    101    101       For SAICAR synthetase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   ACT_SITE    107    107       For SAICAR synthetase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   ACT_SITE    215    215       For SAICAR synthetase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   ACT_SITE    303    303       For AIR carboxylase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   ACT_SITE    332    332       For AIR carboxylase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   SITE        334    334       Essential for AIR carboxylase activity.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|Ref.6}.
FT   MOD_RES      22     22       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9DCL9}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17924679,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      36     36       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9DCL9}.
FT   MOD_RES     107    107       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     238    238       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     247    247       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     274    274       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ      72     72       G -> VTSYKSNR (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_041265.
FT   VARIANT     201    201       K -> N (in dbSNP:rs11549976).
FT                                /FTId=VAR_051884.
FT   MUTAGEN     303    303       H->Y: Loss of AIR carboxylase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   MUTAGEN     332    332       S->A: Loss of AIR carboxylase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   MUTAGEN     334    334       G->A: Loss of AIR carboxylase activity.
FT                                {ECO:0000269|PubMed:17224163}.
FT   MUTAGEN     400    400       S->A: No change of AIR carboxylase
FT                                activity.
FT   CONFLICT    217    217       W -> R (in Ref. 3; CAH18683).
FT                                {ECO:0000305}.
FT   CONFLICT    340    340       S -> T (in Ref. 3; CAH18683).
FT                                {ECO:0000305}.
FT   STRAND       20     22       {ECO:0000244|PDB:2H31}.
FT   STRAND       32     35       {ECO:0000244|PDB:2H31}.
FT   HELIX        54     71       {ECO:0000244|PDB:2H31}.
FT   STRAND       82     88       {ECO:0000244|PDB:2H31}.
FT   STRAND       91     93       {ECO:0000244|PDB:2H31}.
FT   STRAND       97    103       {ECO:0000244|PDB:2H31}.
FT   HELIX       106    111       {ECO:0000244|PDB:2H31}.
FT   STRAND      126    130       {ECO:0000244|PDB:2H31}.
FT   HELIX       142    146       {ECO:0000244|PDB:2H31}.
FT   TURN        147    149       {ECO:0000244|PDB:2H31}.
FT   HELIX       159    180       {ECO:0000244|PDB:2H31}.
FT   HELIX       181    183       {ECO:0000244|PDB:2H31}.
FT   STRAND      186    192       {ECO:0000244|PDB:2H31}.
FT   STRAND      194    197       {ECO:0000244|PDB:2H31}.
FT   TURN        198    200       {ECO:0000244|PDB:2H31}.
FT   STRAND      203    205       {ECO:0000244|PDB:2H31}.
FT   STRAND      213    217       {ECO:0000244|PDB:2H31}.
FT   STRAND      241    243       {ECO:0000244|PDB:2H31}.
FT   HELIX       249    253       {ECO:0000244|PDB:2H31}.
FT   HELIX       256    260       {ECO:0000244|PDB:2H31}.
FT   STRAND      267    273       {ECO:0000244|PDB:2H31}.
FT   HELIX       275    277       {ECO:0000244|PDB:2H31}.
FT   HELIX       278    290       {ECO:0000244|PDB:2H31}.
FT   STRAND      295    299       {ECO:0000244|PDB:2H31}.
FT   TURN        302    304       {ECO:0000244|PDB:2H31}.
FT   HELIX       306    317       {ECO:0000244|PDB:2H31}.
FT   STRAND      323    328       {ECO:0000244|PDB:2H31}.
FT   HELIX       335    342       {ECO:0000244|PDB:2H31}.
FT   STRAND      347    349       {ECO:0000244|PDB:2H31}.
FT   TURN        355    357       {ECO:0000244|PDB:2H31}.
FT   HELIX       358    361       {ECO:0000244|PDB:2H31}.
FT   HELIX       362    364       {ECO:0000244|PDB:2H31}.
FT   HELIX       380    392       {ECO:0000244|PDB:2H31}.
FT   HELIX       396    421       {ECO:0000244|PDB:2H31}.
SQ   SEQUENCE   425 AA;  47079 MW;  E08CF19BC8898F29 CRC64;
     MATAEVLNIG KKLYEGKTKE VYELLDSPGK VLLQSKDQIT AGNAARKNHL EGKAAISNKI
     TSCIFQLLQE AGIKTAFTRK CGETAFIAPQ CEMIPIEWVC RRIATGSFLK RNPGVKEGYK
     FYPPKVELFF KDDANNDPQW SEEQLIAAKF CFAGLLIGQT EVDIMSHATQ AIFEILEKSW
     LPQNCTLVDM KIEFGVDVTT KEIVLADVID NDSWRLWPSG DRSQQKDKQS YRDLKEVTPE
     GLQMVKKNFE WVAERVELLL KSESQCRVVV LMGSTSDLGH CEKIKKACGN FGIPCELRVT
     SAHKGPDETL RIKAEYEGDG IPTVFVAVAG RSNGLGPVMS GNTAYPVISC PPLTPDWGVQ
     DVWSSLRLPS GLGCSTVLSP EGSAQFAAQI FGLSNHLVWS KLRASILNTW ISLKQADKKI
     RECNL
//
